GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 2seventy bio Inc (NAS:TSVT) » Definitions » EV-to-EBIT

2seventy bio (2seventy bio) EV-to-EBIT : -1.25 (As of May. 09, 2024)


View and export this data going back to 2021. Start your Free Trial

What is 2seventy bio EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, 2seventy bio's Enterprise Value is $270.0 Mil. 2seventy bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-216.7 Mil. Therefore, 2seventy bio's EV-to-EBIT for today is -1.25.

The historical rank and industry rank for 2seventy bio's EV-to-EBIT or its related term are showing as below:

TSVT' s EV-to-EBIT Range Over the Past 10 Years
Min: -3.08   Med: -1.46   Max: -0.54
Current: -1.25

During the past 6 years, the highest EV-to-EBIT of 2seventy bio was -0.54. The lowest was -3.08. And the median was -1.46.

TSVT's EV-to-EBIT is ranked worse than
100% of 425 companies
in the Biotechnology industry
Industry Median: 9.54 vs TSVT: -1.25

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. 2seventy bio's Enterprise Value for the quarter that ended in Dec. 2023 was $255.9 Mil. 2seventy bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-216.7 Mil. 2seventy bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -84.69%.


2seventy bio EV-to-EBIT Historical Data

The historical data trend for 2seventy bio's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

2seventy bio EV-to-EBIT Chart

2seventy bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial - - -1.98 -1.37 -1.18

2seventy bio Quarterly Data
Dec18 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.37 -1.96 -2.51 -1.13 -1.18

Competitive Comparison of 2seventy bio's EV-to-EBIT

For the Biotechnology subindustry, 2seventy bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


2seventy bio's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 2seventy bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where 2seventy bio's EV-to-EBIT falls into.



2seventy bio EV-to-EBIT Calculation

2seventy bio's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=269.978/-216.703
=-1.25

2seventy bio's current Enterprise Value is $270.0 Mil.
2seventy bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-216.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


2seventy bio  (NAS:TSVT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

2seventy bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-216.703/255.88264
=-84.69 %

2seventy bio's Enterprise Value for the quarter that ended in Dec. 2023 was $255.9 Mil.
2seventy bio's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-216.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


2seventy bio EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of 2seventy bio's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


2seventy bio (2seventy bio) Business Description

Traded in Other Exchanges
N/A
Address
60 Binney Street, Cambridge, MA, USA, 02142
2seventy bio Inc is a cell and gene therapy company focused on the research, development, and commercialization of transformative treatments for cancer. The company operates in a single segment, focusing on researching, developing and commercializing potentially transformative treatments for cancer.
Executives
Nick Leschly director, officer: President and CEO C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Philip D Gregory officer: Chief Scientific Officer POINT RICHMOND TECH CENTER II, 501 CANAL BOULEVARD SUITE A100, RICHMOND CA 94804
Baird William D Iii officer: Chief Financial Officer C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Yue Tang 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Fund Gp, Llc 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Global Healthcare Master Fund, Lp 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management Gp, Llc 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Kynam Capital Management, Lp 10 percent owner 221 ELM ROAD, PRINCETON NJ 08540
Lin Wei director C/O ERASCA, INC., 10835 ROAD TO THE CURE, SUITE 140, SAN DIEGO CA 92121
Nicola Heffron officer: Chief Operating Officer 2SEVENTY BIO, INC., 60 BINNEY STREET, CAMBRIDGE MA 02142
Marcela V. Maus director 16 RICHMOND CIRCLE, LEXINGTON MA 02421
Ramy Ibrahim director C/O SURFACE ONCOLOGY, 50 HAMPSHIRE STREET, 8TH FLOOR, CAMBRIDGE MA 02139
Sarah Js Glickman director 60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Daniel Lynch director
Denice Torres director 3 RABBIT RUN DRIVE, NEW HOPE PA 18938

2seventy bio (2seventy bio) Headlines

From GuruFocus

2seventy bio Provides Company Outlook for 2023

By Business Wire Business Wire 01-09-2023